Management of Restless Legs Syndrome
- 547 Downloads
Due to developments in diagnosing and treating restless legs syndrome (RLS) over the past decade, there has been a marked increase in the awareness of RLS among both physicians and patients. In fact, it is estimated that 2 % of patients in primary care practices have RLS that is serious and disruptive enough to treat, with the number being diagnosed and treated expected to increase as awareness grows. This chapter aims to provide physicians with guidance to manage this large group of patients properly.
KeywordsDopamine Agonist Ferric Carboxymaltose Impulse Control Disorder Gabapentin Enacarbil Granisetron Hydrochloride
- 9.Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part I: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:1–10.CrossRefGoogle Scholar
- 10.Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part II: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:11–22.CrossRefGoogle Scholar
- 14.Garcia-Borreguero D, Allen RP, Silber MH, Winkleman JW, Högl B, Bainbridge B, et al. White paper summary of recommendations for the prevention and treatment of RLS/WED augmentation. A combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. International Restless Legs Syndrome Study Group website. http://irlssg.org/wp-content/uploads/2015/05/Summary-of-recommendations-RLS-Augmentation-13Aug2015.pdf. Accessed 21 Jan 2016.
- 22.Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, RELOXYN Study Group, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–50.CrossRefPubMedGoogle Scholar
- 27.Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Monplaisi J, Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.CrossRefPubMedGoogle Scholar
- 30.Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, et al. SP710 study group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20.Google Scholar
- 31.Picchietti DL, Hensley JG, Bainbridge JL, Lee KA, Manconi M, McGregor JA, International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev. 2015;22:64–77.CrossRefPubMedGoogle Scholar
- 33.Picchietti DL, Bruni O, de Weerd A, Durmer JS, Kotagal S, Owens JA, Simakajornboon N, International Restless Legs Syndrome Study Group (IRLSSG). Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:1253–9.CrossRefPubMedGoogle Scholar